masivet
ab science s.a. - masitinib mesilate - agenti antineoplastici - cani - trattamento di tumori mastocellulari del cane non resecabili (grado 2 o 3) con recettore tirosin-chinasi modificato c-kit mutato.
camcevi
accord healthcare s.l.u. - leuprorelin mesilate - neoplasie prostatiche - terapia endocrina - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agenti antineoplastici - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
advovet 25 mg/ml
zoetis italia s.r.l. - danofloxacin mesilato - danofloxacin mesilato - 31.73 milligrammo (i), danofloxacin mesilato - 31.73 mg - danofloxacine
tagrisso
astrazeneca ab - osimertinib mesilate - carcinoma, polmone non a piccole cellule - altri agenti antineoplastici, inibitori della proteina chinasi - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.
tafinlar
novartis europharm limited - dabrafenib mesilate - melanoma - agenti antineoplastici - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 e 5. il trattamento adiuvante di melanomadabrafenib in combinazione con trametinib è indicato per il trattamento adiuvante di pazienti adulti con melanoma in stadio iii con un braf v600 mutazione, a seguito di una completa resezione. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.
alsitek
ab science - masitinib mesilate - sclerosi laterale amiotrofica - agenti antineoplastici - trattamento della sclerosi laterale amiotrofica.
masipro
ab science - masitinib mesilate - mastocitosi - agenti antineoplastici - trattamento di mastocitosi.
roclanda
santen oy - latanoprost, netarsudil mesilate - glaucoma, open-angle; ocular hypertension - oftalmologici - roclanda is indicated for the reduction of elevated intraocular pressure (iop) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient iop reduction.
prascend
boehringer ingelheim vetmedica gmbh - pergolide mesilato - pergolide mesilato - 1.31 milligrammo (i), pergolide mesilato - 1.31 mg - pergolide